환자 매개변수의 실시간 평가 및 추적을 가능하게 하는 첨단 센서 및 모니터링 시스템의 발전과 활용 확대가 체외막산소공급장치 시장의 성장을 가속하고 있습니다. 특히 신흥 지역의 헬스케어 산업의 성장은 ECMO 시장에 새로운 기회를 창출하고 있으며, 2024년에는 6억 2,323만 달러의 가치를 넘어 2032년에는 약 9억 3,281만 달러에 이를 것으로 예측됩니다.
이와 더불어, 기술 발전은 ECMO 장비 사용에 대한 의료 전문가의 관행을 강화하고 다양한 임상 환경에서 ECMO 장비의 사용을 확대하는 데 기여하고 있습니다. 이 기술은 환자의 생존율을 향상시켜 2026-2032년 5.75%의 연평균 복합 성장률(CAGR)로 틈새 시장이 성장할 것으로 예측됩니다.
체외막 산소화장치 시장 정의/개요
체외막 산소화 장치는 인공심폐를 통해 혈액을 외부로 순환시키는 장치입니다. 이 장치는 이산화탄소를 효과적으로 제거하면서 산소가 농축된 혈액을 순환계로 되돌려 보냅니다. 심장의 오른쪽에서 인공 심폐로 혈류가 보내집니다. 그 후, 물질은 재가열되어 체내로 되돌아갑니다.
ECMO는 환자의 혈액을 외부 회로로 보내 산소를 공급하고 이산화탄소를 제거한 후 다시 체내로 돌려보내는 장치로, 중증 심부전, 호흡부전(ARDS, 폐렴 등), 심장 수술 후 합병증 등에 주로 사용되며, 신생아 및 소아 의료에 적용되어 선천성 기형 및 중증 호흡곤란 영아들의 생존율을 크게 향상시켰습니다. 선천성 결손증이나 중증 호흡곤란이 있는 영아들의 생존율을 크게 향상시켰습니다. 기능부전에 빠진 장기의 기능을 일시적으로 대신하는 ECMO의 능력은 환자를 안정시키고 기능부전의 근본 원인을 해결하기 위해 의사에게 중요한 창구를 제공합니다.
심폐질환의 유병률 증가는 중요한 문제이며, 에크모 장치를 포함한 의료 개입을 강화해야 할 필요성을 강조하고 있습니다. 심부전, 심근경색, 심정지 등의 심장질환은 인구의 고령화, 좌식 생활습관, 식습관 장애, 고혈압, 비만, 당뇨병 등의 위험인자 유병률 증가 등의 요인으로 인해 증가 추세에 있습니다. 이러한 병태는 기존 치료로는 충분하지 않은 생명을 위협하는 상황으로 이어지는 경우가 많기 때문에 ECMO 시스템은 기저질환 치료 중 산소화와 순환기능을 유지하여 생명유지에 필수적인 역할을 하고 있습니다.
급성 호흡곤란 증후군(ARDS)은 폐의 작은 공기주머니에 액체가 축적되어 혈류로 산소가 효율적으로 이동하는 것을 방해하는 것이 특징입니다. 심각한 호흡기 질환으로 악화될 수 있으며, 효과적인 호흡 보조를 위해 외부의 도움이 필요합니다. 심인성 쇼크는 심장이 갑자기 신체의 요구를 충족시키기에 충분한 혈액을 효과적으로 펌프질할 수 없게 되는 것을 특징으로 하는 심각한 질환으로, 신속하게 대처하지 않으면 장기부전으로 이어질 수 있습니다.
환자 수가 증가함에 따라 심장과 폐를 대신하여 심장과 폐의 휴식과 회복을 촉진하는 ECMO 장비에 대한 수요가 증가하고 있습니다. 이 기술은 대체 치료에 반응하지 않는 환자를 관리하는 중환자실에서 필수적으로 사용되고 있습니다. 심폐 질환의 유병률 증가는 ECMO 장치 시장에 영향을 미치는 중요한 요인입니다.
체외막산소공급장치는 심부전 및 폐부전 환자의 생명 유지에 중요한 역할을 합니다. 핵심적인 문제는 ECMO 장치와 관련된 막대한 비용으로, 종종 수십만 달러에 달할 전망입니다. 또한 이 치료법에는 훈련된 관류 전문의, 중환자실(ICU) 직원, 지속적인 환자 모니터링 등 고도로 전문화된 의료팀이 필요하기 때문에 인건비가 많이 들고, ECMO 치료를 제공할 수 있는 병원의 수가 제한되어 있습니다.
이는 제조 공정에서 최첨단 기술과 혁신적인 재료를 사용하기 때문에 전체 비용에 영향을 미칩니다. 전체 비용은 또한 이러한 기계와 관련된 유지 보수 및 운영 비용에 영향을 받으며, ECMO 치료에는 외과의사, 간호사, 타악기 연주자로 구성된 의료 전문가 팀이 필요하며, 이는 총 치료 비용의 일부가 됩니다.
The growing advancements and the utilization of sophisticated sensor and monitoring systems enabling the real-time assessment and tracking of patient parameters is driving the growth of the Extracorporeal Membrane Oxygenation Machine Market. The growth of the healthcare industry, particularly in developing regions, is creating new opportunities for the ECMO market, surpassing USD 623.23 Million valued in 2024 to reach a valuation of around USD 932.81 Million by 2032.
In addition to this, the advancements in technology are enhancing the practice of healthcare professionals in the use of ECMO machines, thereby contributing to an increased utilization of these machines across diverse clinical environments. This technology is consequently leading to an increase in patient survival rates, enabling the niche market grow at a CAGR of 5.75% from 2026 to 2032.
Extracorporeal Membrane Oxygenation Machine Market: Definition/ Overview
The extracorporeal membrane oxygenation machine (ECMO) involves the external circulation of blood through a heart-lung machine. The device effectively eliminates carbon dioxide while delivering oxygen-enriched blood back to the circulatory system. The right side of the heart directs blood flow to the heart-lung machine. The substance is subsequently reheated and returned to the body.
ECMO works by channeling the patient's blood through an external circuit where it is oxygenated and carbon dioxide is removed before being returned to the body. It is commonly used in cases of severe cardiac failure, respiratory failure (such as ARDS or pneumonia), or post-cardiac surgery complications. ECMO is increasingly being applied in neonatal and pediatric care, where it has significantly improved survival rates for infants with congenital defects or severe respiratory distress. Its ability to temporarily take over the function of failing organs offers physicians a critical window to stabilize patients and address underlying causes of failure.
The increasing prevalence of cardiopulmonary disorders is a significant issue, highlighting the necessity for enhanced medical interventions, including ECMO machines. Cardiac diseases, such as heart failure, myocardial infarction, and cardiac arrest, are on the rise due to factors like aging populations, sedentary lifestyles, poor diets, and increasing prevalence of risk factors such as hypertension, obesity, and diabetes. As these conditions often lead to life-threatening situations where traditional treatments may not suffice, ECMO systems are becoming essential in providing life support by maintaining oxygenation and circulatory functions while underlying conditions are treated.
Acute respiratory distress syndrome (ARDS) is characterized by the accumulation of fluid in the small air sacs of the lungs, impeding the efficient transfer of oxygen into the bloodstream. There is potential for escalation to severe respiratory issues, necessitating external assistance for effective breathing support. Cardiogenic shock represents a severe medical condition characterized by the heart's abrupt inability to effectively pump sufficient blood to meet the body's demands, leading to potential organ failure if not addressed promptly.
The rising patient population is leading to an escalating demand for ECMO machines. ECMO machines serve as substitutes for the heart and lungs, facilitating a period of rest and recovery for these vital organs. This technology has become essential in the intensive care unit for managing patients who do not respond to alternative treatments. The increasing prevalence of cardiopulmonary disorders is a significant factor influencing the ECMO machine market.
The extracorporeal membrane oxygenation machine serves as a critical life support mechanism for individuals experiencing heart or lung failure. The core issue is that the substantial costs associated with ECMO machines, often reaching hundreds of thousands, represent a significant barrier to their utilization despite their remarkable capabilities. The procedure also requires highly specialized medical teams, including trained perfusionists, intensive care unit (ICU) staff, and continuous patient monitoring, which adds to labor costs and limits the number of hospitals capable of offering ECMO treatment.
This results from the utilization of cutting-edge technology and innovative materials in its production process. The overall cost is further influenced by the maintenance and operational expenses associated with these machines. ECMO procedures necessitate specialized teams of healthcare professionals, comprising surgeons, nurses, and percussionists, which contribute to the total treatment expenses.
The oxygenators segment represented the most dominating segment in 2023 and is projected to continue its dominance throughout the forecast period. The rise in chronic diseases, particularly Chronic Obstructive Pulmonary Disease (COPD), alongside the growing need for heart and lung transplantation procedures, can explain this trend. The World Health Organization (WHO) reported that COPD ranked as the third leading cause of death worldwide, accounting for roughly 3.23 million fatalities. The significant increase in mortality rates associated with respiratory and cardiovascular diseases is driving the expansion of the Extracorporeal Membrane Oxygenation Machine Market.
The oxygenators segment is expected to benefit from the overall advancements in ECMO technology and its expanding use in broader clinical settings, including emergency and pediatric care. As healthcare systems adopt ECMO for more patients with severe cardiac and respiratory conditions, demand for high-performance oxygenators will likely increase. Furthermore, ongoing research into biocompatibility and longevity of oxygenators is set to improve patient outcomes and reduce the risks associated with long-term ECMO use, solidifying the market dominance of this segment.
The veno-arterial segment represented the fastest growing CAGR in 2023 and is projected to experience robust growth at a healthy CAGR throughout the forecast period. The increase in utilization can be linked to its effectiveness in managing cases of cardiac arrest, where it plays a crucial role in algorithm-driven life support techniques aimed at reestablishing blood circulation. The rising prevalence of chronic obstructive pulmonary disease (COPD) serves as a significant factor influencing this market segment. A research paper published by BMC Pulmonary Medicine in July 2022 indicated that around 300 million individuals are affected by COPD worldwide, with a prevalence rate of about 12.2%. This underscores a considerable demand for advanced life support technologies such as ECMO machines.
Innovations in VA-ECMO technology, such as more compact and efficient devices, and the integration of real-time monitoring systems, are likely to make it more accessible in emergency care and for long-term patient management. Moreover, expanding use in treating adult and pediatric patients with complex cardiac conditions, combined with advancements in postoperative recovery, will further drive the growth of this segment across hospitals and specialized care centers during the forecast period.
In 2023, the North America Extracorporeal Membrane Oxygenation Machine Market had the dominating share in terms of global revenues. North American market was predominantly represented by the U.S., which held the largest share in the global market. The nation possesses a robust healthcare infrastructure and a significant patient demographic in need of ECMO machines, attributed to the widespread occurrence of chronic illnesses and a notable rate of cardiac and respiratory failures. This has led to a higher demand for advanced life support systems like ECMO, particularly the veno-arterial (VA) type, which provides both cardiac and respiratory assistance in patients suffering from severe cardiac failure. With increasing numbers of patients requiring urgent intervention for heart-related complications, hospitals and medical centers are increasingly adopting ECMO technology as a critical tool for improving survival rates.
The U.S. has maintained its position as a global leader in the innovation of medical devices, drawing in leading manufacturers of ECMO machines. Major market players such as Medtronic, a prominent player in the medical technology sector, has achieved notable advancements in the ECMO machine market. The active participation of the U.S. in the development and approval processes for ECMO machines has led to a notable rise in adoption and expansion within this market segment.
Asia-Pacific region to grow at a robust CAGR during the forecast period. China is projected to maintain a leading role in the East Asia market for extracorporeal membrane oxygenation machines. The increasing utilization of ECMO in pediatric and neonatal care represents a significant factor influencing the industry in China. The evolving healthcare sector in the country is increasingly focused on improving clinical outcomes for infants and children suffering from life-threatening cardiorespiratory conditions.
In cases involving congenital heart defects, respiratory distress syndrome, and various severe infections in neonates, ECMO serves as a critical intervention when standard treatment options are inadequate. China is channeling investments into specialized pediatric and neonatal intensive care units across major hospitals, with ECMO machines emerging as essential equipment. The demand in China is driven by the government's dedication to enhancing health services for children, alongside the growing awareness among healthcare professionals regarding the effectiveness of ECMO in pediatric care.
The Extracorporeal Membrane Oxygenation Machine Market is a dynamic and competitive landscape, with a mix of established players and emerging challengers vying for market share. These players are actively working to strengthen their presence by implementing strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are dedicated to continuously improving their product line to meet the needs of a wide range of customers in different regions.
Some of the key players operating in the Extracorporeal Membrane Oxygenation Machine Market include:
Medtronic, Fresenius Medical Care A.G. & Co. KGAA, Maquet Holding, Getinge Group, Microport, Origin Biomedical, Terumo Cardiovascular Systems Corporation, Livanova plc, Nipro Corporation, Euro sets S.R.L., Cytosorbents Corporation, Abiomed.
In July 2023, the ASAIO Conference showcased BreathMo, an advanced ECMO system, highlighting China's innovation in the field of medical technology. This innovative maglev technology effectively meets the specific medical requirements of patients in China, representing a significant progression in the sector.
In April 2023, Abbott obtained two new approvals from the U.S. Food and Drug Administration (FDA) for its renowned life support system, specifically the CentriMag Blood Pump. The expanded FDA indication facilitates prolonged utilization in adults based on extracorporeal membrane oxygenation (ECMO), an essential life support technique for individuals experiencing cardiac and pulmonary complications.
In November 2022, LivaNova PLC announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation advanced circulatory support system, LifeSPARC. The approval indicates that the LifeSPARC system complies with the standards established by the FDA, allowing for its utilization in the U.S. market.
In July 2022, Inspira Technologies OXY B.H.N Ltd., a leader in life support technology, launched the "Liby" System. This sophisticated life support system is engineered to manage patients experiencing critical heart and lung failure.
In July 2021, Xenios AG, a subsidiary of Fresenius Medical Care, obtained approval from the National Medical Products Administration (NMPA) in China for the utilization of its Xenios Console and patient kits in ECMO therapy. The approval follows the successful registration of two patient kits in China.